c-MET as a Potential Target Therapy Toward Personalized Therapy in Some Pediatric Tumors: An Overview
Although pediatric tumors represent less than 1% of all new cancer diagnoses, they still rank the second in the list of disease-related morbidity and mortality in children in the US. Combining biomarker-driven targeted therapy with individualized genomic analysis is the principle of precision medicine trials. The cellular –mesenchymal-epithelial transition (c-MET) factor receptor signaling pathway plays an important role in many physiological functions including embryological development. It, tightly, regulates changes in cell growth and survival, it also defines the general pattern of invasive growth during normal development.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Wafaa M. Rashed Source Type: research
More News: Cancer | Cancer & Oncology | Child Development | Children | Epithelial Cancer | Hematology | Pediatrics